by barry101 | Apr 10, 2024 | Press Releases
Annamycin demonstrated to be a more potent inhibitor of topoisomerase II-alpha and II-beta while remaining inactive against established cardiomyocyte cultures Results clearly aligned with lack of drug-related cardiotoxic events in patients treated with Annamycin in...
by barry101 | Mar 28, 2024 | Press Releases
Live webcast on Thursday, April 4th at 4:10 PM ET HOUSTON, March 28, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and...
by barry101 | Mar 27, 2024 | Press Releases
Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Thursday, March 28th at 12:00 PM ET HOUSTON, March 27, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad...
by barry101 | Mar 27, 2024 | Press Releases
Patent, once issued, will provide composition of matter protection through 2040, with potential for additional term extension Next-generation anthracycline uses unique lipid-based delivery technology to bring hope to the estimated 58% of AML patients for whom no...
by barry101 | Mar 25, 2024 | Press Releases
– Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 60% (50% CR) in 2nd line AML subjects – AnnAraC has potential to fill significant unmet need and expected to increase 2nd line AML CRs more than double over existing 2nd line...
